摘要
探讨安体舒通对于2型糖尿病肾病患者蛋白尿、血压及肾功能的影响.采用随机双盲交叉的实验方法,20个2型糖尿病肾病患者参与了本课题.在以前降压药的基础上,包括利尿剂、最大推荐剂量的AEC I或和ARB,患者以随机的顺序予安体舒通20 mg/d及安慰剂分别治疗8周,每个治疗阶段后,测定血压、24 h尿蛋白定量及肾小球滤过率(GFR).安体舒通显著地降低了2型糖尿病肾病患者的血压及24 h尿蛋白定量,而肾小球滤过率无显著变化,且24 h尿蛋白定量的变化与血压的变化无明显相关.对于2型糖尿病肾病患者,在推荐最大剂量AEC I或和ARB的基础上,加用适当剂量的安体舒通有额外的肾脏保护作用.表3,参11.
To explore the effect of spironolactone on proteinuria, blood pressure and renal function of type 2 diabetes patients with nephropathy. Twenty type 2 diabetic patients with nephropathy were enrolled in a randomized, double - masked, cross - over study. Patients were treated in random order with spironolactone 20 mg once daily and matched placebo for 8 weeks respectively, in addition to ongoing antihypertentive treatment including diuretics and maximally recommended doses of an ACE inhibitor and/or an ARB. At the end of each treatment period, blood pressure, 24 -h proteinuria and glomerular filtration rate （GFR） were determined. Spironolactone significantly reduced blood pressure and 24 -h proteinuria of type 2 diabetes patients with nephropathy and induced an insignificant reversible reduction in GFR, The change in protein uria did not correlate with the change in blood pressure. Our stud）, suggests that spironolactone safely adds to the reno protective benefits of treatment with maximally recommended doses of ACE inhibitor and/or an ARB in type 2 diabetes patients with nephropathy. 3tabs. , 11 refs.
出处
《湖南环境生物职业技术学院学报》
CAS
2008年第4期41-44,共4页
JOurnal of Hunan Environment Biological Polytechnic
关键词
安体舒通
糖尿病肾病
临床试验
spironolactone
diabetes nephropathy
clinical study
